MediXall Group, Inc. (MDXL)

MediXall Group Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0.31	0.06	0.01	-	0
Revenue Growth (YoY)	422.07%	295.25%	-	-	44.51%
Cost of Revenue	1.24	3.2	3.07	2.53	1.37
Gross Profit	-0.93	-3.14	-3.05	-2.53	-1.37
Selling, General & Admin	2.98	3.36	3.33	2.78	2.05
Other Operating Expenses	-	-0.18	-0.02	0.62	-
Operating Expenses	2.98	3.18	3.31	3.4	2.05
Operating Income	-3.92	-6.32	-6.37	-5.93	-3.42
Interest Expense	-0.65	-0.27	-	-	-
EBT Excluding Unusual Items	-4.56	-6.59	-6.37	-5.93	-3.42
Asset Writedown	-	-0.24	-	-	-
Other Unusual Items	-	-	0.17	-	-
Pretax Income	-4.56	-6.83	-6.2	-5.93	-3.42
Net Income	-4.56	-6.83	-6.2	-5.93	-3.42
Preferred Dividends & Other Adjustments	0.31	0.31	0.25	0.04	-
Net Income to Common	-4.88	-7.14	-6.45	-5.97	-3.42
Shares Outstanding (Basic)	127	117	104	91	74
Shares Outstanding (Diluted)	127	117	104	91	74
Shares Change (YoY)	9.00%	11.96%	14.98%	22.25%	14.03%
EPS (Basic)	-0.04	-0.06	-0.06	-0.07	-0.05
EPS (Diluted)	-0.04	-0.06	-0.06	-0.07	-0.05
Free Cash Flow	-1.23	-3.56	-4.69	-4.14	-2.35
Free Cash Flow Per Share	-0.01	-0.03	-0.04	-0.05	-0.03
Operating Margin	-1265.64%	-10665.08%	-42456.11%	-	-127409.72%
Profit Margin	-1576.10%	-12053.42%	-43014.32%	-	-127409.72%
Free Cash Flow Margin	-397.37%	-6010.77%	-31251.15%	-	-87617.95%
EBITDA	-3.88	-6.29	-6.36	-5.93	-3.42
D&A For EBITDA	0.03	0.04	0	0	0
EBIT	-3.92	-6.32	-6.37	-5.93	-3.42

Source: S&P Capital IQ. Standard template. Financial Sources.